Phase Advance models are a modern sieve of AI & mathematical algorithms to identify medicines that will cure disease and become block busters (what we call “good black swan events”) 7 to 14 years before clinical trials.
Clinical trial success can be affected by unique population differences such as genomics and even diet. An Alzheimer’s patient with particular biomarkers could respond differently to the same drug that benefits a patient from another genetic background. Our models address this tremendous gap in clinical trials.
Whether clients use our models just after discovery or after preclinical work, we can compare the future trial endpoints to market leaders, help design better trials, and reduce the target sample size.
Post PRE-CLINICAL DRUG Development Phase
Phase Advance in silico models of disease progression utilize minimal info to forecast Phase III outcomes.
Immediately Post discovery
Phase Advance models can forecast with minimal details about the molecule or biologic in question.
Our disease models align with the most in-demand therapeutic areas in biotech today, and are expanding continuously.
